S&P/ASX 200 Index shares are up 0.3% to 8,692.5 points on Monday.
The Reserve Bank of Australia will announce its next cash rate decision tomorrow at 2:30pm.
Over the past month, this ASX 200 financial share has fallen 21%.
Bell Potter has a buy recommendation on Mesoblast shares with a $4.45 target.
The Pro Medicus share price is $161.81, up 0.5% today.
5 sentences from our version of the report,
chosen to cover it. Nothing here is written; every line is in the article below.
How
Summarized version
S&P/ASX 200 Index shares are up 0.3% to 8,692.5 points on Monday. The Zip share price is $2, up 0.76% on Monday.
The report’s most important sentence, shortened and in plain words. How
Headline check
All three things this headline claims are in the report.
Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. How this is checked
The article, shortened and in plain language
S&P/ASX 200 Index shares are up 0.3% to 8,692.5 points on Monday.
The market fell to a 15-week low last week as bond yields soared and expectations of an interest rate rise increased.
The Reserve Bank of Australia will announce its next cash rate decision tomorrow at 2:30pm.
If you're looking for buy-the-dip inspiration, experts say these ASX stocks have big potential upside.
The Zip share price is $2, up 0.76% on Monday.
Over the past month, this ASX 200 financial share has fallen 21%.
The Mesoblast share price is $2.08, down 3.7% today.
Bell Potter has a buy recommendation on Mesoblast shares with a $4.45 target.
Analyst John Hester issued an updated note following news of the T-Cell Proliferation Inhibition Assay.
Mesoblast has announced FDA approval of an additional potency assay for Ryoncil.
UBS renewed its buy rating on Xero shares with a $127 target.
Canaccord Genuity upgraded Ramelius Resources shares to a buy call with a $6.15 target.
The Pro Medicus share price is $161.81, up 0.5% today.
Shortened to 1 minute
of reading, this version reads 12.9 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How this outlet filed it, and how we rewrote it
No other newsroom we read has filed on this event, so there is nothing to compare it with yet.
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works